AbbVie, a global biopharmaceutical company, agreed to acquire Cerevel Therapeutics, a biopharmaceutical company focused on developing new therapies, for $8.7bn. "Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade. AbbVie will leverage its deep commercial capabilities, international infrastructure, and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets," Richard A. Gonzalez, AbbVie Chairman and CEO.